The role of the extracellular signal-regulated kinase (ERK) 1 and ERK2 in the neutrophil chemotactic response remains to be identified since a previously used specific inhibitor of MEK1 and MEK2, PD98059, that was used to provide evidence for a role of ERK1 and ERK2 in regulating chemotaxis, has recently been reported to also inhibit MEK5. This issue is made more critical by our present finding that human neutrophils express mitogen-activated protein (MAP) kinase/ERK kinase (MEK)5 and ERK5 (Big MAP kinase), and that their activities were stimulated by the bacterial tripeptide, formyl methionyl-leucyl-phenylalanine (fMLP). Dose response studies demonstrated a bell-shaped profile of fMLP-stimulated MEK5 and ERK5 activation, but this was left-shifted when compared with the profile of fMLP-stimulated chemotaxis. Kinetics studies demonstrated increases in kinase activity within 2 min, peaking at 3-5 min, and MEK5 activation was more persistent than that of ERK5. There were some similarities as well as differences in the pattern of activation between fMLP-stimulated ERK1 and ERK2, and MEK5-ERK5 activation. The up-regulation of MEK5-ERK5 activities was dependent on phosphatidylinositol 3-kinase. Studies with the recently described specific MEK inhibitor, PD184352, at concentrations that inhibited ERK1 and ERK2 but not ERK5 activity demonstrate that the ERK1 and ERK2 modules were involved in regulating fMLPstimulated chemotaxis and chemokinesis. Our data suggest that the MEK5-ERK5 module is likely to regulate neutrophil responses at very low chemoattractant concentrations whereas at higher concentrations, a shift to the ERK1/ERK2 and p38 modules is apparent.Neutrophils, while playing an important role in host defense by killing microbial pathogens, are also responsible for tissue destruction in inflammatory conditions such as rheumatoid arthritis (1) and cystic fibrosis (2). A crucial initial step in this is the recruitment of neutrophils to sites of infection and inflammation by a process known as chemotaxis. A number of studies have reported that the extracellular signal-regulated protein kinase (ERK) 1 1 and ERK2 modules are involved in regulating neutrophil chemotaxis (3-7). These studies showed that PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase/ERK kinase (MEK)1 and MEK2, the immediate upstream regulators of ERK1 and ERK2, inhibited chemotaxis in response to fMLP or IL8. However, PD98059 and another specific MEK1/MEK2 inhibitor, UO126, have recently been reported to also inhibit MEK5, the upstream regulator of ERK5 (8, 9). This therefore creates some doubt as to whether the previous conclusion is valid and whether the MEK5-ERK5 module could also be involved in regulating the chemotactic response.ERK5 or Big MAP kinase (BMK) is a recently described stress-activated MAP kinase (10, 11). This kinase is similar in many aspects to ERK1 and ERK2, but has a unique loop 12 domain within the kinase region, which is followed by an unusually long C terminus. Although murine tissues have been reported...